相关实验视频
Updated: Jun 28, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
糖尿病并发症中的炎症:分子机制和治疗干预措施
Lu Zhao1, Haoran Hu1, Lin Zhang1
1Department of Biology and Medicine College of Life Science, Zhejiang Chinese Medical University Hangzhou China.
MedComm
|April 15, 2024
概括
炎症在糖尿病并发症的发展中起着关键作用,包括糖尿病心肌病,视网膜病,神经病和病. 针对炎症提供了一个有希望的治疗策略,以改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 病理学 病理学 病理学
背景情况:
- 糖尿病 (DM) 是一个主要的全球健康问题,目前的治疗重点是血糖控制和风险因素管理.
- 尽管接受治疗,但DM患者往往会出现严重并发症,影响生活质量.
- 这些糖尿病并发症背后的确切机制尚不清楚,但免疫系统和炎症都在其中.
研究的目的:
- 系统地审查炎症和主要糖尿病并发症之间的关系.
- 探索免疫反应和细胞因子在DM中器官损伤的发病过程中的作用.
- 总结针对炎症的治疗策略,用于管理糖尿病并发症.
主要方法:
- 对糖尿病并发症和炎症研究的系统文献综述.
- 对免疫细胞反应,细胞因子相互作用和器官损伤机制的分析.
- 针对炎症的治疗干预措施的汇编.
主要成果:
- 炎症是糖尿病心肌病,视网膜病,外围神经病和病的发展的一个重要因素.
- 免疫细胞和细胞因子是导致器官损伤的炎症途径的关键调解者.
- 不同的治疗方法,从特定的治疗方法到生活方式的修改,可以针对炎症.
结论:
- 炎症是各种糖尿病并发症的病原体的核心.
- 了解炎症机制可以了解疾病的进展.
- 针对炎症提供了一个可行的治疗途径,以减轻糖尿病并发症并改善患者的健康结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
275
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Pathophysiology of Diabetes
924
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
924
Diabetes: Symptoms, Diagnosis, and Complications
528
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
528
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319

